ETRB

Montana’s expanded right-to-try framework creates an experimental-access pathway for unapproved CTD treatments like Ceres’ nasal spray, but FDA alignment and timing risks remain.

Montana advances a unique right-to-try framework that lets firms sell unapproved, experimental drugs to paying patients via a private review board, with a $12,500 application fee and clinics potentially starting by year-end, but it faces FDA uncertainty and safety concerns.